Table 4 Clinical, functional, and dosimetric factors on RP
Characteristics | RP | No-RP | P |
|---|---|---|---|
Age Mean (range) | 58.5 (38–70) | 59 (40–70) | 0.83 |
Gender (Male/Female) | 25/13 | 23/19 | 0.36 |
KPS Mean (range) | 90.5 (80–100) | 91.9 (80–100) | 0.40 |
AJCC clinical stage (IIIA/ IIIB) | 18/20 | 17/25 | 0.53 |
Histology (AD/SQ/LA/OT) | 17/20/1/0 | 14/23/2/3 | 0.30 |
Tumor site (UM/LO) | 29/9 | 28/14 | 0.34 |
Comorbidity (COPD/CA/DI) | 2/1/0 | 5/2/1 | 0.80 |
Smoking history (NO/CU) | 20/18 | 14/28 | 0.81 |
Chemotherapy (Yes/ No) | 30/8 | 26/16 | 0.10 |
V20 Mean (range) | 38.2 (8.6-63.3) | 29.6 (8.9-60.2) | 0.02 |
V30 Mean (range) | 33.9 (7.9-48.5) | 25.6 (6.6-51.0) | 0.001 |
DLCO (%) Mean (range) | 87.4 (61.3-99.4) | 85.7 (65.4-98.7) | 0.53 |
FEV1 (%) Mean (range) | 86.3 (63.6-99.0) | 83.4 (66.6-99.4) | 0.24 |
FVC (%) Mean (range) | 90.9 (75.6-99.6) | 89.5 (74.3-99.4) | 0.38 |
MLD Mean (range) | 16.7 (5.9-25.6) | 14.0 (7.9-21.3) | 0.008 |
Weight loss ≥ 5% (Yes/ No) | 18/20 | 11/31 | 0.0 |